Company profilePharmaceutical#235 of 1,318 in Pakistan✓ No DRAP alerts

AXIS PHARMACEUTICALS

Pharmaceutical company · 78 brands · 81 molecules

Ranked #17 of 178 companies in Antiinflammatory And Antirheumatic Products

78 registered products 26 pharmaceutical brands 81 distinct molecules 0 DRAP alerts

Company overview

78
registered products
26
pharmaceutical brands
81
distinct molecules
12
therapeutic classes
0
DRAP alerts

AXIS PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 78 product registrations across 81 distinct molecules. Its portfolio is concentrated in Antiinflammatory And Antirheumatic Products and Corticosteroid Combinations, Topical. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Paracetamol4 brands
Clotrimazole2 brands
Domperidone2 brands
Fusidic Acid2 brands
Piroxicam-Beta-Cyclodextrin2 brands
Tizanidine2 brands
Cefixime2 brands

Therapeutic classes

Antiinflammatory And Antirheumatic Products · 10Corticosteroid Combinations, Topical · 5Antihistamines For Systemic Use · 5Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 4Quinolone Antibacterials · 4Other Analgesics And Antipyretics · 4Antiemetics & Antinauseants · 3Blood Glucose Lowering Drugs, Excluding Insulin · 2Macrolides, Lincosamides And Streptogramins · 2Muscle Relaxant · 2Antidiarrheals, Intestinal Antiinflammatory/Antiinfective · 2Cough Expectorant · 2

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for AXIS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.